Wednesday, October 10th, 10:30am-11:25am, Twin Peaks N/S
How are personalized medicine and diagnostic companies positioning themselves in light of the Patient Protection and Affordable Care Act? What are the current trends and future directions in the space? This panel will discuss the current and future role of intellectual property, from both a freedom to operate and a value perspective, in light of recent Court decisions regarding the patentability of laws of nature that frequently surround these discoveries relating to personalized medicine and diagnostics. In particular, how much reliance and value should companies place on such intellectual property and what are the alternatives?
- Eli A. Loots, PhD, Partner, Knobbe Martens
- Patrick Burke, PhD, VP, Strategic Collaborations, Myriad Genetics
- Jonathan Lim, MD, Chairman, CEO, & Co-Founder, Ignyta
- Paul Sheives, Director, Diagnostics & Personalized Medicine Policy, BIO
Jonathan Lim, MD
Jonathan Lim is the Chairman, CEO and Co-Founder of Ignyta, Inc. (formerly NexDx, Inc.), a portfolio company of City Hill Ventures, LLC, a health care investment firm he founded in December 2010. In March 2011, Jonathan co-founded and more recently served as Chairman and CEO of Eclipse Therapeutics, a Biogen Idec spinout which was successfully acquired by Bionomics Ltd (ASX:BNO) in September 2012. Prior to Ignyta from May 2003 to December 2010, Jonathan was President, CEO, and Board Director of Halozyme Therapeutics, Inc. (NASDAQ: HALO), where he led the company's growth from a privately held startup with 5 employees to a publicly traded company with 140 employees and peak market capitalization of nearly $1 billion. Under his leadership, the company went public and raised $300 million from financing and corporate partnerships with Roche and Baxter, achieved two U.S. FDA approvals, and built a deep pipeline of late stage clinical drug candidates.
Jonathan's prior experience includes management consulting at McKinsey & Company, NIH Postdoctoral Fellowship at Harvard, and two years of general surgery residency at New York Hospital-Cornell. He has BS and MS degrees from Stanford, MD from McGill, and MPH from Harvard.
Eli A. Loots, PhD
Eli Loots is a partner in the San Francisco office of Knobbe Martens. Dr. Loots's practice focuses on representing life science clients, from start ups to fortune 500 companies, in the biotechnology space. Dr. Loots has expertise in a wide variety of molecular and cellular technologies, including antibodies, high throughput screening, gene therapy, neuroscience, and stem cell technologies. His practice focuses on client counseling, due diligence, opinion work, and patent preparation and prosecution.
Dr. Loots obtained his PhD in Molecular and Cell Biology from U.C. Berkeley and attended Boalt Hall (U.C. Berkeley) for his law degree.